Immix Biopharma Reports $7.6 Million Net Loss in Q3 2025, Seeks Additional Funding

Immix Biopharma, Inc. reported a net loss of $7.6 million for the third quarter of 2025, a slight increase from the $7.1 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss totaled $18.8 million, compared to $16.9 million for the same period in the previous year. The increase in losses is attributed primarily to rising general and administrative expenses, which reached $3.1 million for the quarter, up from $2.9 million in 2024, and research and development expenses, which increased to $4.6 million from $4.4 million year-over-year. The company’s total operating expenses for the third quarter were $7.7 million, compared to $7.4 million in the prior year.

In terms of financial position, Immix Biopharma reported total assets of approximately $20.1 million as of September 30, 2025, down from $22.9 million at the end of 2024. The decrease in assets is primarily due to a reduction in cash and cash equivalents, which fell to $15.9 million from $17.7 million. The company’s liabilities also increased, with total liabilities rising to $11.8 million from $9.7 million, largely driven by higher accounts payable and accrued expenses, which reached $10.7 million compared to $8.6 million at the end of 2024.

Strategically, Immix Biopharma has made significant advancements in its clinical programs, particularly with its lead candidate, NXC-201, which is currently undergoing clinical trials for the treatment of relapsed/refractory AL Amyloidosis. The company has expanded its clinical trial sites to 18 and has received an $8 million grant from the California Institute for Regenerative Medicine to support the development of NXC-201. Additionally, the company has engaged in various financing activities, including a private placement that raised approximately $9.3 million in September 2025 and an At The Market Offering Agreement that has generated $2.6 million to date.

Looking ahead, Immix Biopharma anticipates continued operational losses as it advances its clinical programs and seeks regulatory approvals. The company has expressed concerns regarding its ability to sustain operations over the next twelve months without additional capital, indicating a need for further financing to support its ongoing activities. Management is actively exploring various funding sources, including equity and debt securities, to ensure the continuation of its business plan. The company’s future financial health will depend on its ability to secure this funding and successfully navigate the complexities of clinical development and commercialization.